We are live on !
Find out more
Aperio Group Portfolio holdings
AUM
$33.8B
Turnover
6.32%
1-Year Est. Return
31.46%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.06%
10 Year Est. Return
–
AUM
$33.8B
AUM Growth
+$4.19B
(+14%)
Cap. Flow
+$264M
Cap. Flow % of AUM
Cap. Flow %
0.78%
Top 10 Holdings %
Top 10 Hldgs %
21.76%
Holding
2,483
New
104
Increased
1,329
Reduced
987
Closed
53
Avg Time Held
4.6
years
Top 10 Avg Time Held
3.4
years
Top 20 Avg Time Held
3.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Unilever
UL
|
+$52.4M |
| 2 |
Tesla
TSLA
|
+$42.1M |
| 3 |
Microsoft
MSFT
|
+$16.9M |
| 4 |
Walt Disney
DIS
|
+$14.5M |
| 5 |
Morgan Stanley
MS
|
+$11.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Unilever NV New York Registry Shares
UN
|
+$48.8M |
| 2 |
AT&T
T
|
+$25.4M |
| 3 |
Johnson & Johnson
JNJ
|
+$20M |
| 4 |
Amazon
AMZN
|
+$15.7M |
| 5 |
Biogen
BIIB
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.68% |
| 2 | Financials | 13.75% |
| 3 | Healthcare | 13.35% |
| 4 | Consumer Discretionary | 11.59% |
| 5 | Communication Services | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2351
Viking Therapeutics
VKTX
$3.4B
| $150K | ﹤0.01% |
26,697
+14,717
| +123% | +$89.1K |
2020 Q3
1 quarter
|
|
|
ATNX
2352
DELISTED
Athenex, Inc. Common Stock
ATNX
| $150K | ﹤0.01% |
678
+114
| +20% | +$28.1K |
2020 Q2
2 quarters
|
|
|
ADAP
2353
DELISTED
Adaptimmune Therapeutics
ADAP
| $149K | ﹤0.01% |
27,556
-6,346
| -19% | -$34.5K |
2020 Q1
3 quarters
|
|
2354
Redhill Biopharma
RDHL
$4.51M
| $149K | ﹤0.01% |
+18
| New | +$162K |
2020 Q4
0 quarters
|
|
|
ATRS
2355
DELISTED
Antares Pharma, Inc.
ATRS
| $149K | ﹤0.01% |
37,381
+4,105
| +12% | +$13.3K |
2019 Q2
6 quarters
|
|
|
APTS
2356
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $148K | ﹤0.01% |
20,031
-4,472
| -18% | -$30.6K |
2017 Q1
15 quarters
|
|
2357
Hackett Group
HCKT
$295M
| $147K | ﹤0.01% |
10,196
-266
| -3% | -$3.69K |
2020 Q3
1 quarter
|
|
2358
FuelCell Energy
FCEL
$991M
| $142K | ﹤0.01% |
+424
| New | +$69.4K |
2020 Q4
0 quarters
|
|
2359
HF Foods Group
HFFG
$83.4M
| $142K | ﹤0.01% |
18,929
-4,415
| -19% | -$33.3K |
2020 Q2
2 quarters
|
|
|
VRAY
2360
DELISTED
ViewRay, Inc.
VRAY
| $142K | ﹤0.01% |
37,109
+1,137
| +3% | +$4.02K |
2020 Q1
3 quarters
|
|
|
TCDA
2361
DELISTED
Tricida, Inc. Common Stock
TCDA
| $140K | ﹤0.01% |
19,916
-56,539
| -74% | -$434K |
2020 Q3
1 quarter
|
|
2362
Arlo Technologies
ARLO
$1.35B
| $139K | ﹤0.01% |
17,818
+6,266
| +54% | +$38.1K |
2020 Q3
1 quarter
|
|
2363
Liberty Latin America Class C
LILAK
$1.57B
| $135K | ﹤0.01% |
13,406
-81
| -0.6% | -$800 |
2016 Q2
18 quarters
|
|
2364
Amarin Corp
AMRN
$242M
| $131K | ﹤0.01% |
1,341
+785
| +141% | +$75.7K |
2020 Q3
1 quarter
|
|
2365
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $130K | ﹤0.01% |
26,615
-8,705
| -25% | -$45.7K |
2014 Q1
27 quarters
|
|
2366
Agenus
AGEN
$290M
| $128K | ﹤0.01% |
2,045
+1,129
| +123% | +$83.8K |
2020 Q2
2 quarters
|
|
2367
Hanmi Financial
HAFC
$933M
| $127K | ﹤0.01% |
11,205
-4,461
| -28% | -$44.6K |
2017 Q3
13 quarters
|
|
2368
Harmonic Inc
HLIT
$1.21B
| $126K | ﹤0.01% |
17,042
+2,915
| +21% | +$19.2K |
2020 Q3
1 quarter
|
|
|
KDMN
2369
DELISTED
Kadmon Holdings, Inc.
KDMN
| $121K | ﹤0.01% |
29,252
+2,649
| +10% | +$10.5K |
2019 Q1
7 quarters
|
|
2370
SM Energy
SM
$9.24B
| $115K | ﹤0.01% |
18,768
-15,127
| -45% | -$51K |
2014 Q1
27 quarters
|
|
2371
MBIA
MBI
$225M
| $112K | ﹤0.01% |
16,994
-2,636
| -13% | -$17.1K |
2014 Q1
27 quarters
|
|
|
LGF.B
2372
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $112K | ﹤0.01% |
10,804
-1,427
| -12% | -$11.9K |
2020 Q2
2 quarters
|
|
2373
Autolus Therapeutics
AUTL
$442M
| $111K | ﹤0.01% |
12,419
+1,047
| +9% | +$11.2K |
2020 Q3
1 quarter
|
|
2374
CytomX Therapeutics
CTMX
$547M
| $110K | ﹤0.01% |
16,834
-3,001
| -15% | -$21.4K |
2020 Q1
3 quarters
|
|
2375
DELISTED
Cymabay Therapeutics
CBAY
| $110K | ﹤0.01% |
19,184
+6,842
| +55% | +$51.8K |
2019 Q2
6 quarters
|
|
Similar funds
LCM
Aperio Group's Q4 2020 Portfolio in Review
As of Q4 2020, Aperio Group held 2,483 positions worth $33.8B, up 14% from $29.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Aperio Group's Q4 2020 filing shows 104 new, 1,329 increased, 987 reduced and 53 closed positions. Its largest new stake was Concentrix: 51,604 shares worth $5.09M. The largest sale was Unilever NV New York Registry Shares, an estimated $48.8M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
- Aperio Group's largest Q4 2020 buy was Concentrix: 51,604 shares worth $5.09M.
- Aperio Group added most to Unilever in Q4 2020, an estimated $52.4M increase.
- Aperio Group's biggest Q4 2020 reduction was AT&T, cutting an estimated $25.4M.
- Aperio Group fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $48.8M.
- Aperio Group's ten largest holdings make up 22% of its $33.8B portfolio in Q4 2020.
- Aperio Group opened 104 new positions and closed 53 in Q4 2020.
- Aperio Group's portfolio value rose 14% quarter-over-quarter to $33.8B.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.